Sign In

Bruce Ettinger, MD

People

Kaiser Permanente Division of Research
2000 Broadway
Oakland, CA 94612




Bruce Ettinger, MD, is an adjunct research scientist at the Kaiser Permanente Northern California Division of Research; and a clinical professor of medicine and radiology at the University of California, San Francisco. His primary research interests are osteoporosis, kidney stones and calcium metabolism, estrogens and other female hormone therapies, menopause, and pharmacoepidemiology. After graduating cum laude from Harvard Medical School, Dr. Ettinger completed his medical residency on the Harvard service of Boston City Hospital. He then served a fellowship in endocrinology and metabolism at the Metabolic Research Unit of the University of California, San Francisco. Dr. Ettinger has authored or co-authored more than 137 peer-reviewed scientific publications, and has written numerous book chapters. He has spent 30 years practicing endocrinology and internal medicine. He is past president of the North American Menopause Society. 

Current Position(s):

  • Adjunct Research Scientist, Division of Research, Kaiser Permanente Northern California
  • Clinical Professor of Medicine and Radiology, University of California, San Francisco

    Primary Research Interests:

    • Osteoporosis
    • Kidney stones and calcium metabolism
    • Hormones
    • Menopause
    • Pharmacoepidemiology

      No results found matching criteria
      No results found matching criteria

      Continuation of postmenopausal hormone replacement therapy: comparison of cyclic versus continuous combined schedules

      Author(s): Ettinger B; Li DK; Klein R

      Menopause. 2018 Nov;25(11):1187-1190.

      PubMed abstract

      Long-term postmenopausal estrogen therapy may be associated with increased risk of breast cancer: a cohort study

      Author(s): Ettinger B; Quesenberry C; Schroeder DA; Friedman G

      Menopause. 2018 Nov;25(11):1191-1194.

      PubMed abstract

      Trends in bisphosphonate initiation within an integrated healthcare delivery system

      Author(s): Hosein RJ; Lo JC; Ettinger B; Li BH; Niu F; Hui RL; Adams AL

      Am J Manag Care. 2017 Dec 01;23(12):e421-e422. Epub 2017-12-01.

      PubMed abstract

      Predicting Adherence and Persistence with Oral Bisphosphonate Therapy in an Integrated Health Care Delivery System

      Author(s): Hui RL; Adams AL; Niu F; Ettinger B; Yi DK; Chandra M; Lo JC

      J Manag Care Spec Pharm. 2017 Apr;23(4):503-512.

      PubMed abstract

      Changing Patterns in Oral Bisphosphonate Initiation in Women between 2004 and 2012

      Author(s): Lee DR; Ettinger B; Chandra M; Hui RL; Lo JC

      J Am Geriatr Soc. 2017 Feb 02.

      PubMed abstract

      Applying ethnic-specific bone mineral density T-scores to Chinese women in the USA

      Author(s): Lo JC; Kim S; Chandra M; Ettinger B

      Osteoporos Int. 2016 Jul 28.

      PubMed abstract

      The association of race/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy

      Author(s): Lo JC; Hui RL; Grimsrud CD; Chandra M; Neugebauer RS; Gonzalez JR; Budayr A; Lau G; Ettinger B

      Bone. 2016 Jan 6.

      PubMed abstract

      Racial/ethnic differences in hip and diaphyseal femur fractures

      Author(s): Lo JC; Zheng P; Grimsrud CD; Chandra M; Ettinger B; Budayr A; Lau G; Baur MM; Hui RL; Neugebauer R

      Osteoporos Int. 2014 Jun 26.

      PubMed abstract

      Osteoporosis: Who should be treated? Who should be screened?

      Author(s): Stuenkel CA; Ettinger B

      In: Osteoporosis. 4th edition. Oxford: Academic Press; 2013.

      PubMed abstract

      Validation of FRC, a Fracture Risk Assessment Tool, in a Cohort of Older Men: The Osteoporotic Fractures in Men Study

      Author(s): Ettinger B; Liu H; Blackwell T; Hoffman AR; Ensrud KE; Orwoll ES; For the Osteoporotic Fracture in Men (MrOS) Research Group

      J Clin Densitom. 2012 Jul-Sep;15(3):334-42. Epub 2012 Mar 21.

      PubMed abstract

      Fracture risk tool validation in an integrated healthcare delivery system

      Author(s): Lo JC; Pressman AR; Chandra M; Ettinger B

      Am J Manag Care. 2011 Mar;17(3):188-94.

      PubMed abstract

      Updated fracture incidence rates for the US version of FRAX

      Author(s): Ettinger B; Black DM; Dawson-Hughes B; Pressman AR; Melton LJ 3rd

      Osteoporos Int. 2010 Jan;21(1):25-33. Epub 2009 Aug 25.

      PubMed abstract

      High-dose corticosteroid exposure and osteoporosis intervention in adults

      Author(s): Che M; Ettinger B; Nguyen MT; Pressman AR; Johnston J

      Ann Allergy Asthma Immunol. 2006 Oct;97(4):497-501.

      PubMed abstract

      Hormone predictors of bone mineral density changes during the menopausal transition

      Author(s): Sowers MR; Jannausch M; McConnell D; Little R; Greendale GA; Finkelstein JS; Neer RM; Johnston J; Ettinger B

      J Clin Endocrinol Metab. 2006 Apr;91(4):1261-7. Epub 2006 Jan 10.

      PubMed abstract

      Use of raloxifene among women with a history of breast cancer

      Author(s): Habel LA; Pressman A; Ettinger B; Sidney S; Suh-Burgmann B; Fehrenbacher L; Quesenberry CP

      Breast Cancer Res Treat. 2006 Mar;96(2):123-9.

      PubMed abstract

      Effect of isoflavones on lipids and bone turnover markers in menopausal women

      Author(s): Schult TM; Ensrud KE; Blackwell T; Ettinger B; Wallace R; Tice JA

      Maturitas. 2004 Jul 15;48(3):209-18.

      PubMed abstract

      Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate

      Author(s): Ettinger B; San Martin J; Crans G; Pavo I

      J Bone Miner Res. 2004 May;19(5):745-51. Epub 2004 Jan 19.

      PubMed abstract

      Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial

      Author(s): Tice JA; Ettinger B; Ensrud K; Wallace R; Blackwell T; Cummings SR

      JAMA. 2003 Jul 9;290(2):207-14.

      PubMed abstract

      Endogenous hormones and bone turnover markers in pre- and perimenopausal women: SWAN

      Author(s): Sowers MR; Greendale GA; Bondarenko I; Finkelstein JS; Cauley JA; Neer RM; Ettinger B

      Osteoporos Int. 2003 May;14(3):191-7. Epub 2003 Apr 11.

      PubMed abstract

      Ethnic variation in bone density in premenopausal and early perimenopausal women: effects of anthropometric and lifestyle factors

      Author(s): Finkelstein JS; Lee ML; Sowers M; Ettinger B; Neer RM; Kelsey JL; Cauley JA; Huang MH; Greendale GA

      J Clin Endocrinol Metab. 2002 Jul;87(7):3057-67.

      PubMed abstract

      For osteoporosis, are two antiresorptive drugs better than one?

      Author(s): Ettinger B; Bilezikian JP

      J Clin Endocrinol Metab. 2002 Mar;87(3):983-4.

      PubMed abstract

      Reversal by medical treatment of endometrial hyperplasia caused by estrogen replacement therapy

      Author(s): Figueroa-Casas PR; Ettinger B; Delgado E; Javkin A; Vieder C

      Menopause. 2001 Nov-Dec;8(6):420-3.

      PubMed abstract

      Prevalence and determinants of osteoporosis drug prescription among patients with high exposure to glucocorticoid drugs

      Author(s): Ettinger B; Chidambaran P; Pressman A

      Am J Manag Care. 2001 Jun;7(6):597-605.

      PubMed abstract

      Concomitant medication use in postmenopausal women using estrogen therapy

      Author(s): Small R; Friedman GD; Ettinger B

      Menopause. 2001 Summer;8(2):120-6.

      PubMed abstract

      Risk for fracture in women with low serum levels of thyroid-stimulating hormone

      Author(s): Bauer DC; Ettinger B; Nevitt MC; Stone KL; Study of Osteoporotic Fractures Research Group

      Ann Intern Med. 2001 Apr 3;134(7):561-8.

      PubMed abstract

      Raloxifene FAQs: Perspectives on the first approved SERM - where are we now? Part 2.

      Author(s): Birge SF; Cosman F; Ettinger B

      Menopause Manag. 2001;10(2):21-29.

      PubMed abstract

      Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

      Author(s): Ettinger B; Black DM; Mitlak BH; Knickerbocker RK; Nickelsen T; Genant HK; Christiansen C; Delmas PD; Zanchetta JR; Stakkestad J; Gluer CC; Krueger K; Cohen FJ; Eckert S; Ensrud KE; Avioli LV; Lips P; Cummings SR

      JAMA. 1999 Aug 18;282(7):637-45.

      PubMed abstract

      Differences in calcium metabolism between black and white men and women

      Author(s): Bikle DD; Ettinger B; Sidney S; Tekawa IS; Tolan K

      Miner Electrolyte Metab. 1999 May-Jun;25(3):178-84.

      PubMed abstract

      Association of total and central adiposity measures with fasting insulin in a biracial population of young adults with normal glucose tolerance: the CARDIA study

      Author(s): Sidney S; Lewis CE; Hill JO; Quesenberry CP Jr; Stamm ER; Scherzinger A; Tolan K; Ettinger B

      Obes Res. 1999 May;7(3):265-72.

      PubMed abstract

      Health-related quality of life in economic evaluations for osteoporosis: whose values should we use?

      Author(s): Gabriel SE; Kneeland TS; Melton LJ 3rd; Moncur MM; Ettinger B; Tosteson AN

      Med Decis Making. 1999 Apr-Jun;19(2):141-8.

      PubMed abstract

      Unexpected vaginal bleeding and associated gynecologic care in postmenopausal women using hormone replacement therapy: comparison of cyclic versus continuous combined schedules

      Author(s): Ettinger B; Li DK; Klein R

      Fertil Steril. 1998 May;69(5):865-9.

      PubMed abstract

      Evaluation of homogeneous high-density lipoprotein cholesterol assay on a BM/Hitachi 747-200 analyzer

      Author(s): Lin MJ; Hoke C; Ettinger B

      Clin Chem. 1998 May;44(5):1050-2.

      PubMed abstract